Ocular Therapeutix (OCUL) Other Non-Current Assets (2013 - 2026)
Ocular Therapeutix (OCUL) recorded quarterly Other Non-Current Assets of $1.6 million in Q1 2026, little changed quarter-over-quarter from $1.6 million in Q4 2025, and little changed on a YoY basis from $1.6 million in Q1 2025.
Ocular Therapeutix (OCUL) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Ocular Therapeutix's Other Non-Current Assets history runs 14 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (changed 0.0% YoY), while the FY2025 annual figure was $1.6 million, changed 0.0% from the prior year.
- Other Non-Current Assets was $1.6 million for Q1 2026 at Ocular Therapeutix, roughly flat from $1.6 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.8 million in Q1 2022 to a low of $1.6 million in Q4 2023.
- Historically, Other Non-Current Assets has averaged $1.7 million across 5 years, with a median of $1.6 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets changed 0.0% in 2022, then decreased 8.5% in 2023.
- A 5-year view of Other Non-Current Assets shows it stood at $1.8 million in 2022, then fell by 8.5% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024, then changed by 0.0% to $1.6 million in 2025, then changed by 0.0% to $1.6 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.6 million (Q1 2026), $1.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ocular Therapeutix | 2.12 Bn | 2.12 Bn | 9.46 Mn | 1.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 1.61 Mn |
| Sep 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 1.61 Mn |
| Mar 31, 2025 | 1.61 Mn |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 1.61 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 1.76 Mn |
| Mar 31, 2023 | 1.76 Mn |
| Dec 31, 2022 | 1.76 Mn |
| Sep 30, 2022 | 1.76 Mn |
| Jun 30, 2022 | 1.76 Mn |
| Mar 31, 2022 | 1.76 Mn |
| Dec 31, 2021 | 1.76 Mn |
| Sep 30, 2021 | 1.76 Mn |
| Jun 30, 2021 | 1.76 Mn |